ABSTRACT RNA interference (RNAi) is an ancient biological mechanism used to defend
against external invasion. It theoretically can silence any disease-related genes in a …

Short-interfering RNA (siRNA)-induced RNAi responses have great potential to treat a wide
variety of human diseases from cancer to pandemic viral outbreaks to Parkinson's Disease …

A main challenge in realizing the full potential of nucleic acid therapeutics is efficient
delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well …

Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …

Small interfering RNA (siRNA) enables efficient target gene silencing by employing a RNA
interference (RNAi) mechanism, which can compromise gene expression and regulate gene …

Recent years have seen unprecedented activity in the development of RNA-silencing
oligonucleotide therapeutics for metabolic diseases. Improved oligonucleotide design and …

In this study, we systematically collected relevant literature in the past five years on the
intervention of natural polysaccharides in alcoholic liver disease (ALD) and reviewed the …

Pancreatic cancer is currently one of the deadliest of the solid malignancies, whose
incidence and death rates are increasing consistently during the past 30 years …

Background: Delivery of foreign cargoes into cells is of great value for bioengineering
research and therapeutic applications. Objective: In this study, we proposed and established …

摘要近期, RNA 干扰(RNAi) 制药公司Alnylam 开发的小干扰RNA (siRNA) 药物ONPATTRO™(
Patisiran) 相继获得美国食品与药物管理局和欧盟委员会批准上市, 用于治疗成人患者的遗传性 …